Divalproex sodium
Divalproex sodium is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Divalproex sodium; Generic name: DIVALPROEX SODIUM; Manufacturer: Cardinal Health 107, LLC.
| Brand name | Divalproex sodium |
|---|---|
| Generic name | DIVALPROEX SODIUM |
| Manufacturer | Cardinal Health 107, LLC |
| Used for | 1 INDICATIONS AND USAGE Divalproex sodium delayed-release capsule is an anti-epileptic drug indicated for : Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1) 1.1 Epilepsy Divalproex sodium delayed-release capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium delayed-release capsules are also indicated for use as sole and adjunctive |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Divalproex sodium delayed-release capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) ( 2.2 ) • Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 ) • Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; |
| Warnings | WARNING: LIFE THREATENING ADVERSE REACTIONS Hepatotoxicity General Population : Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should b |
| Active ingredient(s) | DIVALPROEX SODIUM |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0816a066-9ee3-4c23-944d-3539fc2c12bf |